1. Introduction {#sec1}
===============

Platelet aggregation is caused by "inside-out signaling" and "outside-in signaling", which is absolutely essential for the formation of a hemostatic plug when normal blood vessels are injured. However, platelet aggregation can also cause circulatory disorders, such as thrombosis, atherosclerosis, and myocardial infarction [@bib1].

Various agonists \[i.e., collagen, thrombin, adenosine diphosphate (ADP)\] induce "inside-out signaling" to bind adhesive proteins (i.e., fibrinogen, fibronectin, vitronectin) to glycoprotein IIb/IIIa (αIIb/β~3~) and platelet membrane integrin, then "outside-in signaling" is subsequently processed to cause a series of signal events (i.e., Ca^2+^ mobilization, granule secretion, clot retraction) [@bib2], [@bib3], [@bib4]. Through these signaling events, intravascular platelets finally are aggregated at the site of vascular wall injury, which contributes to intensity of the formation of thrombus.

Vasodilator-stimulated phosphoprotein (VASP) phosphorylation inhibits VASP affinity for contractile protein filamentous actin, and fibrinogen binding to αIIb/β~3~ to inhibit the final common pathway for platelet aggregation [@bib5], [@bib6]. On the contrary, phosphatidylinositol 3-kinase (PI3K)/Akt phosphorylation involves αIIb/β~3~ activation [@bib7]. Therefore, the upregulation of VASP phosphorylation and the downregulation of PI3K/Akt phosphorylation are paramount important indexes to understand αIIb/β~3~ activation, and are very useful for evaluating the antiplatelet effect of substances or compounds. For instance, a major catechin analogue, (-)-epigallocatechin-3-gallate from green tea, and caffeic acid are known to produce cAMP via adenylate cyclase activation and subsequently phosphorylates VASP (Ser^157^) to inhibit \[Ca^2+^\]~i~ mobilization [@bib8], [@bib9]. In addition, abciximab, etifibatide, tirofiban, and lamifiban are known as αIIb/β~3~ antagonists [@bib10], [@bib11].

Ginseng, the root of *Panax ginseng* Meyer, has been used frequently in traditional Oriental medicine, and is known to have various pharmacological activities such as anti-inflammatory action, antioxidation, antitumor, antidiabetes, and antihepatotoxicity effects [@bib12], [@bib13]. It was recently reported that Korean Red Ginseng has an effect on cardiovascular disease, which is characterized with regard to reduction of blood pressure and arterial stiffness by inhibition of Rho kinase [@bib14], anticoagulation by prolonged prothrombin and activated partial thromboplastin time [@bib15], endothelium relaxation by nitric oxide-cyclic guanosine monophosphate (cGMP) pathway [@bib16], and inhibition of hypercholesterolemia-induced platelet aggregation [@bib17]. In our previous report, we demonstrated that total saponin from Korean Red Ginseng (KRG-TS) is a beneficial traditional Oriental medicine in platelet-mediated thrombotic disease via suppression of cyclooxygenase-1 (COX-1) and thromboxane A~2~ (TXA~2~) synthase to inhibit production of thromboxane A~2~ [@bib18]. In addition, KRG-TS is involved in increase of cAMP levels and subsequent reduction of \[Ca^2+^\] mobilization in thrombin-induced rat platelet aggregation [@bib19]. With regard to the effects of ginsenosides on platelet aggregation, it is well known that ginsenoside Rg3 (G-Rg3) and its chemical derivatives (dihydroxyginsenoside Rg3, ginsenoside Rp1) have antiplatelet effects by regulating the aggregation-inhibiting molecule cAMP, and aggregation-stimulating molecules [@bib20], [@bib21]. In this study, we investigated the novel effects of KRG-TS on the phosphorylation of VASP and dephosphorylation of PI3K and Akt affecting on fibrinogen and fibronectin binding to αIIb/β~3~. In addition, we found that ginsenoside Ro (G-Ro), an oleanane type saponin, in KRG-TS has a potent antiplatelet effect.

2. Materials and methods {#sec2}
========================

KRG-TS was obtained from R&D Headquarter, Korea Ginseng Corporation (Daejeon, Korea). Ginsenoside Ro was purchased from Ambo Institute (Daejon, Korea). Thrombin was purchased from Chrono-Log Corporation (Havertown, PA, USA). A CytoSelect 48-well cell adhesion assay kit (Fibronectin-Coated, Colorimetric Format) was purchased from Cell Biolabs (San Diego, CA, USA). A-kinase inhibitor Rp-8-Br-cAMPS, G-kinase inhibitor Rp-8-Br-cGMPS, A-kinase activator 8-(4-chlorophenylthio)-cAMP (pCPT-cAMP), and G-kinase activator 8-Br-cGMP and 2-acetoxymethyl (Fura 2-AM) were obtained from Sigma Chemical Corporation (St. Louis, MO, USA). PI3K inhibitor wortmannin and cAMP enzyme immunoassay (EIA) kit were obtained from Cayman Chemical (Ann Arbor, MI, USA). Anti-phosphor-VASP (Ser^157^), anti-phosphor-VASP (Ser^239^), anti-PI3K, anti-phosphor-PI3K (Tyr^458^), anti-Akt, anti-phosphor-Akt (Ser^473^), and anti-rabbit immunoglobulin G (IgG)-horseradish peroxidase conjugate (HRP), and lysis buffer were obtained from Cell Signaling (Beverly, MA, USA). αIIb/β~3~ inhibitor eptifibatide, GR 144053, and anti-β-actin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Polyvinylidene difluoride (PVDF) membrane was obtained from GE Healthcare (Piscataway, NJ, USA). Enhanced chemiluminesence solution (ECL) was obtained from GE Healthcare (Chalfont St, Giles, Buckinghamshire, UK). Fibrinogen Alexa Fluor 488 conjugate was obtained from Invitrogen Molecular Probes (Eugene, OR, USA).

2.1. Preparation of washed human platelets {#sec2.1}
------------------------------------------

Human platelet-rich plasma (PRP) anticoagulated with acid-citrate-dextrose solution (0.8% citric acid, 2.2% sodium citrate, 2.45% glucose) was obtained from Korean Red Cross Blood Center (Changwon, Korea). The PRP was centrifuged for 10 min at 125 *g* to remove a few red blood cells, and was centrifuged for 10 min at 1,300 *g* to obtain the platelet pellets. The platelets were washed two times with washing buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO~3~, 0.36 mM NaH~2~PO~4~, 5.5 mM glucose, and 1 mM Na~2~EDTA, pH 6.5). The washed platelets were then resuspended in suspension buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO~3~, 0.36 mM NaH~2~PO~4~, 0.49 mM MgCl~2~, 5.5 mM glucose, 0.25% gelatin, pH 6.9) to a final concentration of 5 × 10^8^/mL. All of the aforementioned procedures were carried out at 25°C to avoid platelet aggregation from any effect of low temperatures. The Korea National Institute for the Bioethics Policy Public Institutional Review Board (Seoul, Korea) approved these experiments (PIRB12-072).

2.2. Measurement of platelet aggregation {#sec2.2}
----------------------------------------

Washed human platelets (10^8^/mL) were preincubated for 3 min at 37°C in the presence of 2mM exogenous CaCl~2~ with or without substances, then stimulated with thrombin (0.05 U/mL) for 5 min. Aggregation was monitored using an aggregometer (Chrono-Log Corporation, Havertown, PA, USA) at a constant stirring speed of 1,000 rpm. Each aggregation rate was calculated as an increase in light transmission. The suspension buffer was used as the reference (transmission 0). KRG-TS was dissolved in the platelet suspension buffer (pH 6.9).

2.3. Western blot for analysis of VASP-, PI3K-, and Akt-phosphorylations {#sec2.3}
------------------------------------------------------------------------

Washed human platelets (10^8^/mL) were preincubated with or without substances in the presence of 2mM CaCl~2~ for 3 min and then stimulated with thrombin (0.05 U/mL) for 5 min at 37°C in an aggregometer at a constant stirring speed of 1,000 rpm. The reactions were terminated by adding an equal volume (250 μL) of lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM Na~2~EDTA, 1 mM EGTA, 1% Triton X-100, 2.5mM sodium pyrophosphate, 1 mM serine/threonine phosphatase inhibitor β-glycerophosphate, 1 mM adenosine triphosphatase, alkaline and acid phosphatase, and protein phosphotyrosine phosphatase inhibitor Na~3~VO~4~, 1 μg/mL serine and cysteine protease inhibitor leupeptin, and 1 mM serine protease and acetylcholinesterase inhibitor phenylmethanesulfonyl fluoride, pH 7.5). Platelet lysates containing the same protein (15 μg) were used for the analysis. Protein concentrations were measured using a bicinchoninic acid protein assay kit (Pierce Biotechnology, Rockford, IL, USA). The effects of substances on VASP-, PI3K, and Akt-phosphorylation were analyzed using Western blotting. A 6-8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (1.5 mm gel) was used for electrophoresis and a PVDF membrane was used for protein transfer from the gel. The dilutions for anti-phosphor-VASP (Ser^157^), anti-phosphor-VASP (Ser^239^), anti-PI3K, anti-phosphor-PI3K (Tyr^458^), anti-Akt, anti-phosphor-Akt (Ser^473^), and anti-rabbit IgG-HRP were 1:1,000, 1:1,000, 1:1,000, 1:1,000, 1:1,000, 1:1,000, and 1:10,000, respectively. The membranes were visualized using ECL. The blots were analyzed using the Quantity One, version 4.5 (BioRad, Hercules, CA, USA).

2.4. Determination of fibrinogen binding to αIIb/β~3~ {#sec2.4}
-----------------------------------------------------

Washed human platelets (10^8^/mL) were preincubated for 3 min at 37°C with or without substances in the presence of 2mM CaCl~2~ and then stimulated with thrombin (0.05 U/mL) in the presence of Alexa Flour 488-human fibrinogen (30 μg/mL) for 5 min at 37°C. The reaction was stopped by the addition of 0.5% paraformaldehyde in phosphate buffered saline, and the samples were placed in the dark. Alexa Fluor 488-fibrinogen binding to platelets was determined using flow cytometry (BD Biosciences, San Jose, CA, USA) and fibrinogen binding to αIIb/β~3~ was analyzed using cellQuest software (BD Biosciences, San Jose, CA, USA).

2.5. Determination of fibronectin adhesion {#sec2.5}
------------------------------------------

Adhesion assay was performed with the CytoSelect 48-well cell adhesion assay kit (Cell Biolabs, San Diego, CA, USA). The plates were coated with fibronectin or bovine serum albumin (BSA) as a negative control. Washed human platelets (10^8^/mL) were incubated for 60 min at 37°C in the presence of thrombin (0.05 U/mL) with or without various concentrations of KRG-TS. After five times washing with phosphate buffered saline, cell stain solution was added and the plates were incubated at room temperature for 10 min. After washing five times, extraction solution was added and the plates were incubated for 10 min. Each sample was transferred to a 96-well microtiter plate and measured with Synergy HT Multi-Model Microplate Reader (BioTek Instruments, Winooski, VT, USA) at an optical density of 560 nm.

2.6. Assay of platelet-mediated fibrin clot retraction {#sec2.6}
------------------------------------------------------

Human PRP 250 μL were transferred into a polyethylene tube to avoid clot adherence, then were preincubated with or without KRG-TS (150 μg/mL) for 10 min at 37°C, and subsequently stimulated with thrombin (0.05 U/mL) for 5 min at 37°C. Pictures of fibrin clot were taken at 5 min using a digital camera, and its quantification was carried out by measurement of clot area using the Image J Software (version 1.46, National Institutes of Health, Bethesda, MD, USA). Percentage of clot retraction was calculated as follows:

2.7. Determination of cytosolic-free Ca^2+^ (\[Ca^2+^\]~i~) {#sec2.7}
-----------------------------------------------------------

Human PRP was incubated with 5μM Fura 2-AM at 37°C for 60 min. Because Fura 2-AM is light sensitive, the tube containing the PRP was covered with aluminum foil during loading. The Fura 2-loaded washed platelets were prepared using the procedure described previously and platelets (10^8^/mL) were preincubated for 3 min at 37°C with or without G-Ro (200 μM) in the presence of 2mM CaCl~2,~ then stimulated with thrombin (0.05 U/mL) for 5 min for evaluation of \[Ca^2+^\]~i~. Fura 2 fluorescence was measured with a spectrofluorometer (SFM 25, BioTeck Instrument, Milan, Italy) with an excitation wavelength that was changed every 0.5 s from 340 nm to 380 nm; the emission wavelength was set at 510 nm. The \[Ca^2+^\]~i~ values were calculated using the method of Grynkiewicz et al [@bib22].

2.8. Measurement of cAMP {#sec2.8}
------------------------

Washed human platelets (10^8^/mL) were preincubated for 3 min at 37°C with or without G-Ro (200 μM) in the presence of 2 mM CaCl~2~, then stimulated with thrombin (0.05 U/mL) for 5 min for platelet aggregation. The aggregation was terminated by the addition of 80% ice-cold ethanol. cAMP was measured with Synergy HT Multi-Model Microplate Reader (BioTek Instruments) using a cAMP EIA kit.

2.9. Statistical analyses {#sec2.9}
-------------------------

The experimental results are expressed as the mean ± standard deviation accompanied by the number of observations. Data were assessed by analysis of variance (ANOVA). If this analysis indicated significant differences among the group means, then each group was compared by the Newman-Keuls method. Statistical analysis was performed according to the SPSS 21.0.0.0 (SPSS Inc., Chicago, IL, USA). A *p* value \< 0.05 was considered to be statistically significant.

3. Results {#sec3}
==========

3.1. Effects of KRG-TS on thrombin-induced human platelet aggregation {#sec3.1}
---------------------------------------------------------------------

The concentration of thrombin-induced maximal human platelet aggregation was ∼0.05 U/mL ([Fig. 1](#fig1){ref-type="fig"}A). Therefore, thrombin (0.05 U/mL) was used as the human platelet agonist in this study. In intact platelets, the light transmission in response to various concentrations of KRG-TS (25 μg/mL, 50 μg/mL, 100 μg/mL, 150 μg/mL) was 1.3 ± 0.6% (at 25 μg/mL of KRG-TS), 1.3 ± 0.6% (at 50 μg/mL of KRG-TS), 1.3 ± 0.6% (at 100 μg/mL of KRG-TS), and 1.3 ± 0.6% (at 150 μg/mL of KRG-TS), respectively, which were not significantly different from that (1.0 ± 0.0%) in resting platelets without KRG-TS ([Fig. 1](#fig1){ref-type="fig"}B). When washed human platelets (10^8^/mL) were activated with thrombin, the aggregation rate was increased up to 87.8 ± 5.7%. However, various concentrations of KRG-TS (25--150 μg/mL) significantly reduced thrombin-stimulated platelet aggregation in a dose-dependent manner ([Figs. 1](#fig1){ref-type="fig"}B, C), and the half-maximal inhibitory concentration (IC~50~) was ∼45 μg/mL ([Fig. 1](#fig1){ref-type="fig"}D). This IC~50~ is low as compared with that (81.1 μg/mL) from rat platelets [@bib19]. In addition, 150 μg/mL of KRG-TS inhibited to 95.9% thrombin--induced human platelet aggregation (87.8 ± 5.7%).

3.2. Effects of KRG-TS on VASP phosphorylation {#sec3.2}
----------------------------------------------

Because 150 μg/mL of KRG-TS ([Fig. 1](#fig1){ref-type="fig"}B) significantly inhibited thrombin-induced platelet aggregation, we used 150 μg/mL of KRG-TS to evaluate its effect on various signaling molecules. KRG-TS activated the phosphorylation of VASP (Ser^157^), an A-kinase substrate ([Fig. 2](#fig2){ref-type="fig"}A, lane 3). Next we investigated whether VASP (Ser^157^) phosphorylation by KRG-TS is dependent on cAMP/A-kinase pathway. A-kinase inhibitor Rp-8-Br-cAMPS ([Fig. 2](#fig2){ref-type="fig"}A, lane 4) potently decreased KRG-TS (150 μg/mL)-induced VASP (Ser^157^) phosphorylation. A-kinase activator pCPT-cAMP stimulated also VASP (Ser^157^) phosphorylation, indicating dependence on cAMP ([Fig. 2](#fig2){ref-type="fig"}A, lane 5). Although G-kinase activator 8-Br-cGMP stimulated VASP (Ser^239^) phosphorylation, indicating dependence on cGMP ([Fig. 2](#fig2){ref-type="fig"}B, lane 5), KRG-TS (150 μg/mL) did not increase the VASP (Ser^239^) phosphorylation ([Fig. 2](#fig2){ref-type="fig"}B, lane 3).

3.3. Effects of KRG-TS on fibrinogen binding to αIIb/β~3~ {#sec3.3}
---------------------------------------------------------

Next, we investigated whether the VASP (Ser^157^) phosphorylation by KRG-TS was involved in inhibition of fibrinogen binding to αIIb/β~3~. As shown in [Fig. 3](#fig3){ref-type="fig"}A, thrombin activated the fibrinogen binding to αIIb/β~3~ ([Figs. 3](#fig3){ref-type="fig"}A, B), and increased to 92.1 ± 2.1% fibrinogen binding to αIIb/β~3~ ([Figs. 3](#fig3){ref-type="fig"}A and B) from that (1.7 ± 0.2%) of intact platelets, control ([Table 1](#tbl1){ref-type="table"}). However, KRG-TS dose (25--150 μg/mL) dependently inhibited thrombin-activated fibrinogen binding to αIIb/β~3~ ([Figs. 3](#fig3){ref-type="fig"}A-c--f, 3B), and KRG-TS (150 μg/mL) inhibited to 91.6% fibrinogen binding as compared with that (92.1 ± 2.1%) by thrombin ([Table 1](#tbl1){ref-type="table"}). Although it is known that cAMP- and cGMP-increasing compounds are involved in inhibition of αIIb/β~3~ via cAMP/A-kinase, and cGMP/G-kinase pathway [@bib23], [@bib24], in this study, because KRG-TS did not phosphorylated VASP (Ser^239^) ([Fig. 2](#fig2){ref-type="fig"}B), we investigated whether the inhibition of fibrinogen binding to αIIb/β~3~ by KRG-TS resulted from cAMP/A-kinase pathway. A-kinase activator pCPT-cAMP inhibited thrombin-induced fibrinogen binding to αIIb/β~3~ ([Figs. 4](#fig4){ref-type="fig"}A--b, B), which indicates that cAMP/A-kinase pathway involves inhibition of fibrinogen binding to αIIb/β~3~ in thrombin-induced platelet aggregation. KRG-TS (150 μg/mL)-inhibited fibrinogen binding to αIIb/β~3~ was elevated by A-kinase inhibitor Rp-8-Br-cAMPS ([Figs. 4](#fig4){ref-type="fig"}A--a, B), and its stimulatory degree was 350% as compared with that (7.7%) by both KRG-TS and thrombin ([Table 1](#tbl1){ref-type="table"}).

3.4. Effects of KRG-TS on PI3K/Akt phosphorylation {#sec3.4}
--------------------------------------------------

As apposed to the phosphorylated VASP, PI3K/Akt phosphorylation stimulates αIIb/β~3~ activation and fibrinogen binding [@bib25], [@bib26]. Thus, we investigated the effect of KRG-TS on phosphorylation of PI3K and its downstream molecule Akt. Thrombin potently phosphorylated PI3K ([Fig. 5](#fig5){ref-type="fig"}, lane 2) as compared with that ([Fig. 5](#fig5){ref-type="fig"}, lane 1) of intact platelets. However, KRG-TS ([Fig. 5](#fig5){ref-type="fig"}, lanes 3 and 4) inhibited thrombin-induced PI3K phosphorylation. Moreover, PI3K inhibitor wortmannin, negative control, suppressed thrombin-induced PI3K phosphorylation ([Fig. 5](#fig5){ref-type="fig"}, lane 5). Thrombin elevated the phosphorylation of PI3K target molecule Akt ([Fig. 6](#fig6){ref-type="fig"}, lane 2). However, KRG-TS inhibited thrombin-induced Akt phosphorylation ([Fig. 6](#fig6){ref-type="fig"}, lanes 3 and 4).

3.5. Effects of KRG-TS on adhesion to fibronectin {#sec3.5}
-------------------------------------------------

Integrin αIIbβ~3~ also served as a fibronectin receptor on platelets and occupancy of this receptor is essential for platelet adhesion. Therefore, we determined whether KRG-TS interferes with fibronectin binding to αIIbβ~3~. As shown in [Fig. 7](#fig7){ref-type="fig"}, thrombin did not adhere platelets to bovine serum albumin (BSA), negative control, but thrombin potently adhered platelets to fibronectin. These mean that thrombin induced fibronectin adhesion to αIIb/β~3~ of platelets, but not BSA ([Fig. 7](#fig7){ref-type="fig"}A). KRG-TS (25--150 μg/mL) dose dependently decreased thrombin-induced fibronectin adhesion, and αIIbβ~3~ inhibitors (eptifibatide and GR 144053) also inhibited thrombin-induced fibronectin adhesion. Next, we investigated whether fibronectin inhibition by KRG-TS was resulted from cAMP/A-kinase activation. A-kinase inhibitor Rp-8-Br-cAMPS increased KRG-TS-decreased fibronectin binding to αIIbβ~3~ ([Fig. 7](#fig7){ref-type="fig"}B). Moreover, A-kinase activator pCPT-cAMP inhibited thrombin-induced fibronectin binding to αIIb/β~3~ ([Fig. 7](#fig7){ref-type="fig"}B), which means that cAMP/A-kinase activation is involved in inhibition of fibronectin adhesion.

3.6. Effects of KRG-TS on retraction of fibrin clot {#sec3.6}
---------------------------------------------------

Activation of αIIbβ~3~ (inside-out signaling) by platelet agonists induces fibrinogen binding to αIIbβ~3~, and leads to outside-in αIIbβ~3~ signaling, containing clot retraction, platelet spreading, stable adhesion, granule secretion, protein phosphorylation, platelet contraction, \[Ca^2+^\]~i~ mobilization, and calpain activation [@bib27], [@bib28], [@bib29]. Here, we investigated the effect of KRG-TS on retraction of thrombin-induced fibrin clot, an index of outside-in αIIbβ~3~ signaling. Photographs in [Fig. 8](#fig8){ref-type="fig"}A show that thrombin stimulated the formation of fibrin clot, and the retraction of fibrin clot. The degree of retraction was determined from quantitation of fibrin clot area by Image J Software (version 1.46, National Institutes of Health, Bethesda, MD, USA). As shown in [Fig. 8](#fig8){ref-type="fig"}B, thrombin potently retracted fibrin clot, and increased to 60% the rate of clot retraction as compared with that without thrombin intact (55 ± 1.3 mm^2^). However, KRG-TS suppressed thrombin-retracted fibrin clot, and its inhibitory degree was 82% as compared with that by thrombin (22 ± 1.1 mm^2^; [Fig. 8](#fig8){ref-type="fig"}B).

3.7. Effects of G-Ro on platelet aggregation, \[Ca^2+^\]~i~ mobilization, and cAMP production {#sec3.7}
---------------------------------------------------------------------------------------------

In our previous report [@bib30], we showed that protopanaxadiol type saponins (G-Ra1, G-Rb1, G-Rb2, G-Rb3, G-Rc, G-Rd, G-Rh2), and protopanaxatriol type saponins (G-Re, G-Rf, G-Rg1, G-Rg2, G-Rh1) have no antiplatelet effect on thrombin-induced human platelet aggregation. In this study, however, we found that G-Ro, an oleanane type saponin, has a potent antiplatelet effect. When human platelets (10^8^/mL) were stimulated by thrombin (0.05 U/mL), platelet aggregation was potently increased ([Table 2](#tbl2){ref-type="table"}). However, G-Ro inhibited thrombin-induced platelet aggregation, its inhibitory degree was 52.0% as compared with that by thrombin (86.7 ± 1.5%; [Table 2](#tbl2){ref-type="table"}). G-Ro increased to 89.1% the production of Ca^2+^-antagonistic cAMP, and decreased to 77.3% the level of aggregating-molecule \[Ca^2+^\]~i~ in thrombin-induced platelet aggregation ([Table 2](#tbl2){ref-type="table"}).

4. Discussion {#sec4}
=============

Of several aggregation inhibiting molecules, cAMP and cGMP are essential for inhibition of platelet aggregation. These cyclic nucleotides generate various biological functions (i.e., VASP phosphorylation, IP~3~R phosphorylation) via cAMP/A-kinase- or cGMP/G-kinase-pathway.

A downstream pathway of both cAMP/A-kinase and cGMP/G-kinase is involved in VASP phosphorylation to inhibit αIIb/β~3~ activity. Ser^157^ at 50 kDa of VASP \[VASP (Ser^157^)\] is phosphorylated by the cAMP/A-kinase pathway, whereas Ser^239^ at 50 kDa of VASP \[VASP (Ser^239^)\] is phosphorylated by the cGMP/G-kinase pathway [@bib24], [@bib31]. KRG-TS markedly phosphorylated A-kinase substrate VASP (Ser^157^), but did not phosphorylate G-kinase substrate VASP (Ser^239^) in thrombin-induced platelet aggregation. These results suggest that the VASP (Ser^157^) phosphorylation by KRG-TS is possibly achieved by stimulating cAMP/A-kinase pathway, as evidenced by the fact that KRG-TS elevated cAMP only of cAMP and cGMP in thrombin-induced platelet aggregation [@bib19]. Otherwise, A-kinase inhibitor Rp-8-Br-cAMPS would not decrease KRG-TS-elevated VASP (Ser^157^) phosphorylation. In addition, A-kinase inhibitor Rp-8-Br-cAMPS increased KRG-TS-inhibited fibrinogen binding to αIIb/β~3~. In this study, we have established that the inhibitory effect by KRG-TS on thrombin-induced αIIb/β~3~ activation is due to cAMP/A-kinase-dependent VASP (Ser^157^) phosphorylation, as evidenced by the fact that cAMP/A-kinase pathway involves suppression of αIIb/β~3~ activation [@bib3], [@bib4], [@bib32]. cAMP-elevating agents (i.e., cilostamide, cilostazole, and forskolin) are known to inhibit PI3K- and Akt-phosphorylation in thrombin-induced platelet aggregation [@bib33]. Therefore, KRG-TS that increases cAMP level [@bib19] may be involved in inhibition of PI3K/Akt phosphorylation, and subsequently could participate in suppression of αIIb/β~3~ activation.

Platelet adhesion is the first step in the hemostatic response and various adhesive proteins such as von Willebrand factor, collagen, and fibronectin can mediate as substrates for platelet adhesion [@bib34]. Fibronectin adhesion is mediated by both α~5~β~1~ and αIIb/β~3~, and subsequently is involved in platelet spreading, plug formation, and a series of events of outside-in signaling [@bib34], [@bib35]. We clearly showed that KRG-TS strongly attenuated fibronectin binding to αIIb/β~3~ in a cAMP/A-kinase-dependent manner, as verified that A-kinase inhibitor Rp-8-Br-cAMPS increased KRG-TS-reduced fibronectin binding in thrombin-induced platelet aggregation.

Fibrinogen binding to αIIb/β~3~ is involved in fibrin clot retraction, which is an index of thrombus intensification [@bib27], and is known to be involved in promotion of atheroprogression [@bib36], [@bib37]. If so, inhibition of fibrinogen-, fibronectin-binding and clot retraction is a clear evidence that KRG-TS might protect platelet-mediated thrombotic disease.

Platelet aggregation is generated at the site of vascular wall injury, and is involved in the formation of thrombus. During the formation of thrombus, platelets release cell growth proteins such as platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) in their α-granule [@bib38], [@bib39]. It is well established that PDGF and VEGF induce the proliferation of fibroblast, vascular smooth cells, and epithelial cells, and subsequently enhance the rate of atherosclerosis lesion progression [@bib40], [@bib41], [@bib42], [@bib43], [@bib44]. The progression of atherosclerosis is strongly induced by inflammatory cells such as monocyte/macrophage, and neutrophil [@bib45]. Although KRG-TS has antiplatelet effects, if KRG-TS does not inhibit inflammation by leukocytes, the progression of atherosclerosis lesion would be generated at the site of vascular wall injury, and a question regarding antiplatelet effects of KRG-TS might be raised. Byeon et al. [@bib46] reported that saponin fraction inhibits lipopolysaccharide (LPS)-induced inflammation, and it is well reviewed that ginsenosides have anti-inflammatory effects by inhibiting the production of various pro-inflammatory mediators \[i.e., prostaglandin E~2~, nitric oxide (NO)\] [@bib47]. Recently, it was reported that Korean Red Ginseng saponin fraction downregulates LPS-induced proinflammatory mediators (i.e., NO, interleukin-1β) [@bib48]. In addition, Yang et al. [@bib49] clarified that protopanaxadiol saponin fraction inhibits inflammatory actions via suppression of p38-, JNK2-, and TANK \[tumor necrosis factor receptor-associated factor (TRAF) family member-associated nuclear factor-κ-B activator\]-binding kinase-1-linked pathway and their corresponding transcription factors (i.e., activation transcription factor 2, interferon regulatory transcription factor 3). Considering these previous reports [@bib46], [@bib47], [@bib48], [@bib49], it is thought that KRG-TS may have antithrombotic, and antiatherosclerotic effects without generation of inflammation and progression of atherosclerotic lesion at the site of vascular wall injury. Therefore, KRG-TS is highlighted as a nontoxic antiplatelet compound, and could be clinically applied to the prevention of platelet-mediated thrombosis. This is supported from reports that Korean Red Ginseng has protective effects on rat carotid artery thrombosis *in vivo* [@bib50], and both ginseng and ginsenoside are beneficial candidates for prevention of cardiovascular disease [@bib51].

Long-term (4--5 years) intake of red ginseng products (i.e., water extract, tea, drink) is known to inhibit platelet aggregation, blood coagulation, and hyperlipidemia such as indexes of thrombotic diseases and atherosclerosis, and their effects were also well sustained in the patients who have obesity, hyperlipidemia, and hypertension [@bib52], [@bib53].

Hwang et al. [@bib17] reported that dietary water-extract of Korean Red Ginseng (KRG-WE) inhibited collagen-induced rabbit platelet aggregation under hypercholesterolemia causing atherosclerosis such as cardiovascular disease, and KRG-WE had a strong antiplatelet effects as compared with those caused by lovastatin, an anticholesterolemic drug. Oral administration (250--500 μg/kg-body weight-rat) of KRG-WE significantly inhibited agonists (i.e., ADP, collagen)-induced platelet aggregation, and KRG-WE (300 μg/mL, 500 μg/mL) inhibited agonists (i.e., ADP, collagen, etc.)-induced washed rabbit platelet aggregation *in vitro* [@bib49]. If these are physiological concentrations (300 μg/mL, 500 μg/mL) of KRG-WE to inhibit rat and rabbit platelet aggregation in *in vitro* and *in vivo*, because it is thought that we used KRG-TS (150 μg/mL) is low concentration as compared with that of KRG-WE *in vitro* (300 μg/mL, 500 μg/mL), in this study, it is unknown whether *in vitro* KRG-TS (150 μg/mL)-mediated antiplatelet effects are also expressed *in vivo*. These should be studied in the future.

With regard to the G-Ro, Sanada et al. [@bib54] reported that G-Ro is contained in *Panax ginseng*, Choi [@bib55] reviewed that G-Ro (0.045 w/w %), and G-Rg3 (20S, 0.006 w/w %) and G-Rg3 (20R, 0.014 w/w %) are contained in *Panax ginseng*, but not in *Panax notoginseng* (Sanchi ginseng), and *Panax quinquefolius* (American ginseng). It is known that G-Ro (1mM) inhibited arachidonic acid-induced platelet aggregation and fibrin formation *in vitro* [@bib56], and G-Ro (10--50 mg/kg body weight-rat) administration activated fibrinolysis, indicating the inhibition of fibrin thrombi [@bib57]. Accordingly, when antiplatelet-mediated 200μM (about 191.4 mg/kg) of G-Ro (MW. 957.1) is administered to animals, it is unknown whether thrombin-induced platelet aggregation would also be inhibited *in vivo*. However, considering thrombin is involved in platelet aggregation and fibrin formation, it is thought that G-Ro 200μM (191.4 mg/kg) would be involved in inhibition of platelet aggregation and fibrin formation. Currently, G-Ro is known to have anti-inflammatory effects [@bib58]. If so, it is thought that G-Ro may also have a protective effect on thrombosis through inhibition of platelet aggregation and inflammation.

It is known that G-Ro does not inhibit collagen-induced \[Ca^2+^\]~i~ mobilization [@bib59], however, in this study, we confirmed that G-Ro inhibits \[Ca^2+^\]~i~ mobilization by increasing Ca^2+^-antagonistic cAMP in thrombin-induced platelet aggregation. Therefore, it is thought that G-Ro-elevated cAMP also may be involved in VASP (Ser^157^) phosphorylation in the same manner that KRG-TS activated cAMP-dependent VASP (Ser^157^) phosphorylation.

G-Rg3 (20S, 20R) is known to have antiplatelet effects by regulating various aggregating molecules [@bib20], [@bib21]. Recently, we also reported that only G-Rg3 (20S, 20R) of protopanaxadiol saponin have inhibitory effects on thrombin-induced platelet aggregation [@bib30]. Antiplatelet effects of G-Ro and G-Rg3 indicated that *Panax ginseng* would have an excellent antithrombotic effect by inhibiting platelet aggregation than that by any ginsengs, and G-Ro and G-Rg3 (20S, 20R) are major compounds in KRG-TS only of *Panax ginseng*.

In conclusion, the most important result of this study is that KRG-TS significantly inhibits binding of adhesive proteins (i.e., fibrinogen, fibronectin) to αIIb/β~3~ by activating the phosphorylation of VASP (Ser^157^) and dephosphorylation of PI3K and Akt, which contribute to inhibition of thrombotic formation. Therefore, we suggest that KRG-TS may be a physiologically effective negative regulator in thrombosis, atherosclerosis, and myocardial infarction via inhibition of platelet aggregation.
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![Effects of total saponin Korean Red Ginseng (KRG-TS) on thrombin-induced human platelet aggregation. (A) The concentration threshold of thrombin on human platelet aggregation. (B) Effects of KRG-TS on thrombin-induced human platelet aggregation. (C) The inhibitory effects of KRG-TS on thrombin-induced human platelet aggregation. (D) The half maximal inhibitory concentration (IC~50~) value of KRG-TS in thrombin-stimulated human platelet aggregation. Measurement of platelet aggregation was carried out as described in the *Materials and methods* section. The rate of inhibition by KRG-TS was recorded as the percentage of the thrombin induced aggregation rate. The IC~50~ value of KRG-TS was calculated according to the four-parameter log fit method. The data are expressed as the mean ± standard deviation (*n* = 4). \**p* \< 0.05 versus the thrombin-stimulated platelets.](gr1){#fig1}

![Effects of total saponin Korean Red Ginseng (KRG-TS) on vasodilator-stimulated phosphoprotein (VASP) phosphorylation. (A) Effect of KRG-TS on VASP (Ser^157^) phosphorylation. Lane 1, Intact platelets (base); Lane 2, Thrombin (0.05 U/mL); Lane 3, Thrombin (0.05 U/mL) + KRG-TS (150 μg/mL); Lane 4, Thrombin (0.05 U/mL) + KRG-TS (150 μg/mL) + Rp-8-Br-cAMPS (250 μM); and Lane 5, Thrombin (0.05 U/mL) + pCPT-cAMP (1mM). (B) Effect of KRG-TS on VASP (Ser^239^) phosphorylation. Lane 1, Intact platelets (base); Lane 2, Thrombin (0.05 U/mL); Lane 3, Thrombin (0.05 U/mL) + KRG-TS (150 μg/mL); Lane 4, Thrombin (0.05 U/mL) + KRG-TS (150 μg/mL) + Rp-8-Br-cGMPS (250μM); and Lane 5, Thrombin (0.05 U/mL) + 8-Br-cGMP (1mM). Western blotting was performed as described in the *Materials and methods* section. The data are expressed as the mean ± standard deviation (*n* = 4). \**p* \< 0.05 versus the thrombin-stimulated platelets. \*\* *p* \< 0.05 versus the thrombin-stimulated platelets in the presence of KRG-TS (150 μg/mL). cAMP = cyclic adenosine monophosphate; cGMP = cyclic adenosine monophosphate; pCPT-cAMP = 8-(4-chlorophenylthio)-cAMP](gr2){#fig2}

![Effects of total saponin Korean Red Ginseng (KRG-TS) on thrombin-induced fibrinogen binding. (A) The flow cytometry histograms on fibrinogen binding: a, intact platelets (base); b, thrombin (0.05 U/mL); c, thrombin (0.05 U/mL) + KRG-TS (25 μg/mL); d, thrombin (0.05 U/mL) + KRG-TS (50 μg/mL); e, thrombin (0.05 U/mL) + KRG-TS (100 μg/mL); and f, thrombin (0.05 U/mL) + KRG-TS (150 μg/mL). (B) Effects of KRG-TS on thrombin-induced fibrinogen binding (%). Determination of fibrinogen binding to αIIb/β~3~ was carried out as described in the *Materials and methods* section. The data are expressed as the mean ± standard deviation (*n* = 4). \* *p* \< 0.05 versus the thrombin-stimulated platelets.](gr3){#fig3}

![Effects of total saponin Korean Red Ginseng (KRG-TS) on thrombin-induced fibrinogen binding in the presence of A-kinase inhibitor (Rp-8-Br-cAMPS). (A) The flow cytometry histograms on fibrinogen binding: a, thrombin (0.05 U/mL) + KRG-TS (150 μg/mL) + Rp-8-Br-cAMPS (250μM) and b, thrombin (0.05 U/mL) + pCPT-cAMP (1mM). (B) Effects of KRG-TS on thrombin-induced fibrinogen binding (%). Determination of fibrinogen binding to αIIb/β~3~ was carried out as described in the *Materials and methods* section. The data are expressed as the mean ± standard deviation (*n* = 4). \* *p* \< 0.05 versus the thrombin-stimulated platelets. \*\* *p* \< 0.05 versus the thrombin-stimulated platelets in the presence of KRG-TS (150 μg/mL). cAMP = cyclic adenosine monophosphate; pCPT-cAMP = 8-(4-chlorophenylthio)-cAMP](gr4){#fig4}

![Effects of total saponin Korean Red Ginseng (KRG-TS) on PI3K phosphorylation. Lane 1, Intact platelets (base). Lane 2, Thrombin (0.05 U/mL). Lane 3, Thrombin (0.05 U/mL) + KRG-TS (100 μg/mL). Lane 4, Thrombin (0.05 U/mL) + KRG-TS (150 μg/mL). Lane 5, Thrombin (0.05 U/mL) + wortmannin (10μM). Western blotting was performed as described in the *Materials and methods* section. The data are expressed as the mean ± standard deviation (*n* = 4). \* *p* \< 0.05 versus the thrombin-stimulated platelets.](gr5){#fig5}

![Effects of total saponin Korean Red Ginseng (KRG-TS) on Akt phosphorylation. Lane 1, Intact platelets (base). Lane 2, Thrombin (0.05 U/mL). Lane 3, Thrombin (0.05 U/mL) + KRG-TS (100 μg/mL). Lane 4, Thrombin (0.05 U/mL) + KRG-TS (150 μg/mL). Western blotting was performed as described in the *Materials and methods* section. The data are expressed as the mean ± standard deviation (*n* = 4). \* *p* \< 0.05 versus the thrombin-stimulated platelets.](gr6){#fig6}

![Effects of total saponin Korean Red Ginseng (KRG-TS) on thrombin-induced fibronectin adhesion. (A) Inhibitory effects of KRG-TS on fibronectin adhesion. (B) Effects of KRG-TS on thrombin-induced fibronectin adhesion in the presence of A-kinase inhibitor (Rp-8-Br-cAMPS). Measurement of fibronectin adhesion was carried out as described in the *Materials and methods* section. BSA = bovine serum albumin (negative control). The data are expressed as the mean ± standard deviation (*n* = 4). \* *p* \< 0.05 versus the thrombin-stimulated platelets. \*\* *p* \< 0.05 versus the thrombin-stimulated platelets in the presence of KRG-TS (150 μg/mL).](gr7){#fig7}

![Effects of total saponin Korean Red Ginseng (KRG-TS) on fibrin clot retraction. (A) Photographs of fibrin clot. (B) Effects of KRG-TS on thrombin-retracted fibrin clot. Quantification of fibrin clot retraction was performed as described in the *Materials and methods* section. (1) = (base -- thrombin)/base × 100, 2) = \[base -- (thrombin + KRG-TS)\]/base × 100, 3) = \[thrombin -- (thrombin + KRG-TS)\]/thrombin × 100. The data are expressed as the mean ± standard deviation (*n* = 4). \* *p* \< 0.05 versus the thrombin-stimulated platelets.](gr8){#fig8}

###### 

Effects of Rp-8-Br-cAMPS on fibrinogen binding[1)](#tbl1fn1){ref-type="table-fn"}

                             Fibrinogen Binding (%)   Δ(%)
  -------------------------- ------------------------ -------------------------------------------
  Intact platelets           1.7 ± 0.2                ---
  Thrombin (0.05 U/mL)       92.1 ± 2.1               ---
                                                      
  KRG-TS (150 μg/mL)         7.7 ± 0.2                −91.6 [2)](#tbl1fn2){ref-type="table-fn"}
   + Thrombin (0.05 U/mL)                             
                                                      
  KRG-TS (150 μg/mL)         34.8 ± 0.4               +350 [3)](#tbl1fn3){ref-type="table-fn"}
   + Thrombin (0.05 U/mL)                             
   + Rp-8-Br-cAMPS (250μM)                            

cAMP, cyclic adenosine monophosphate; KRG-TS, total saponin Korean Red Ginseng

Data from [Fig. 3](#fig3){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}B

Δ (%) = \[(KRG-TS + Thrombin) -- Thrombin\]/Thrombin × 100

Δ (%) = \[(KRG-TS + Thrombin + Rp-8-Br-cAMPS) -- (KRG-TS + Thrombin)\] / (KRG-TS + Thrombin)\] × 100

###### 

Effects of G-Ro on platelet aggregation, \[Ca^2+^\]~i~ mobilization, and cyclic adenosine monophosphate production in thrombin-induced human platelet activation

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                         Aggregation (%)   Δ (%)                                       cAMP\                    Δ (%)                                       Ca^2+^ (nM)     Δ (%)
                                                                                                       (pmol/10^8^ platelets)                                                               
  -------------------------------------- ----------------- ------------------------------------------- ------------------------ ------------------------------------------- --------------- --------------------------------------------
  Basal (control)                        \-                                                            4.8 ± 0.3                ---                                         102.4 ± 0.5     ---

  Thrombin (0.05 U/mL)                   86.7 ± 1.5        ---                                         4.6 ± 0.1                0                                           655.7 ± 38.7    +540.3 [2)](#tbl2fn2){ref-type="table-fn"}

  G-Ro (200 μM) + Thrombin (0.05 U/mL)   41.7 ± 2.5\*      −52.0 [1)](#tbl2fn1){ref-type="table-fn"}   8.7 ± 1.0\*              +89.1 [1)](#tbl2fn1){ref-type="table-fn"}   149.0 ± 3.8\*   −77.3 [1)](#tbl2fn1){ref-type="table-fn"}
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The data are expressed as the mean ± standard deviation (*n* = 4)

\* *p* \< 0.05 versus the thrombin-stimulated platelets

cAMP = cyclic adenosine monophosphate

Δ (%) = \[Thrombin -- (G-Ro + Thrombin) / Thrombin × 100

(Basal -- Thrombin)/Basal × 100

[^1]: These two authors contributed equally to this work.
